Oragenics, Inc. Announces Proposed Public Offering
June 24 2024 - 6:43PM
Oragenics, Inc. (NYSE: OGEN) (“Oragenics” or the “Company”), a
company focused on developing unique, intranasal pharmaceuticals
for the treatment of neurological disorders, today announced that
it intends to offer and sell shares of its common stock (or
pre-funded warrants in lieu thereof). All of the securities to be
sold in the offering are to be offered by Oragenics. The offering
is subject to market conditions, and there can be no assurance as
to whether or when the offering may be completed, or as to the
actual size or terms of the offering.
The Company intends to use the net proceeds from the
offering to fund the continued development of its ONP-002
product candidate and for general corporate purposes and working
capital.
Dawson James Securities, Inc. is the sole placement agent for
the offering.
The offering is being made pursuant to a shelf registration
statement on Form S-3 (File No. 333-269225), including a base
prospectus, filed with the U.S. Securities and Exchange Commission
(the “SEC”) on January 13, 2023, and declared effective on January
25, 2023. The offering will be made only by means of a prospectus
supplement and accompanying prospectus. The preliminary prospectus
supplement and accompanying prospectus describing the terms of the
proposed offering will be filed with the SEC and will be available
on the SEC’s website located at http://www.sec.gov. Electronic
copies of the preliminary prospectus supplement may be obtained,
when available, from Dawson James Securities, Inc., 101 North
Federal Highway, Suite 600, Boca Raton, FL 33432 or by telephone at
(561) 391-5555, or by email at investmentbanking@dawsonjames.com.
Before investing in this offering, interested parties should read
in their entirety the prospectus supplement and the accompanying
prospectus and the other documents that Oragenics has filed with
the SEC that are incorporated by reference in such prospectus
supplement and the accompanying prospectus, which provide more
information about Oragenics and such offering.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About OragenicsOragenics is a development-stage
biotechnology company focused on nasal delivery of pharmaceutical
medications in neurology and fighting infectious diseases,
including drug candidates for treating mild traumatic brain injury
(mTBI), also known as concussion, and for treating Niemann Pick
Disease Type C (NPC), as well as proprietary powder formulation and
an intranasal delivery device. For more information, please
visit www.oragenics.com.
Forward Looking StatementsThis communication
contains “forward-looking statements” within the meaning of the
safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995, including with regard to the Company’s ability
to regain compliance with the NYSE American’s continued listing
standards by October 18, 2025. These forward-looking statements are
based on management’s beliefs and assumptions and information
currently available. The words "believe," "expect," "anticipate,"
"intend," "estimate," "project" and similar expressions that do not
relate solely to historical matters identify forward-looking
statements. Investors should be cautious in relying on
forward-looking statements because they are subject to a variety of
risks, uncertainties, and other factors that could cause actual
results to differ materially from those expressed in any such
forward-looking statements. These factors include, but are not
limited to those described in our Form 10-K and other filings with
the U.S. Securities and Exchange Commission. All information set
forth in this press release is as of the date hereof. You should
consider these factors in evaluating the forward-looking statements
included in this press release and not place undue reliance on such
statements. We do not assume any obligation to publicly provide
revisions or updates to any forward-looking statements, whether as
a result of new information, future developments or otherwise,
should circumstances change, except as otherwise required by
law.
Oragenics, Inc.Janet Huffman, Chief Financial
Officer813-286-7900jhuffman@oragenics.com
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Oragenics (AMEX:OGEN)
Historical Stock Chart
From Jul 2023 to Jul 2024